These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36537885)

  • 21. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain.
    Überall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2011 Jul; 27(7):1385-94. PubMed ID: 21561313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.
    Mercadante S; Porzio G; Aielli F; Averna L; Ficorella C; Casuccio A
    Support Care Cancer; 2013 Aug; 21(8):2335-9. PubMed ID: 23564072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
    Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
    PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breakthrough cancer pain in 2020.
    Løhre ET; Thronæs M; Klepstad P
    Curr Opin Support Palliat Care; 2020 Jun; 14(2):94-99. PubMed ID: 32332210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study.
    Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1134-1139. PubMed ID: 36808361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study.
    Katz NP; Gajria KL; Shillington AC; Stephenson JJ; Harshaw Q
    Postgrad Med; 2017 Jan; 129(1):32-39. PubMed ID: 27846789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating breakthrough pain in oncology.
    Mercadante S
    Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription.
    Villegas Estévez F; López Alarcón MD; Alonso Babarro A; Olay Gayoso L; de Castro J; Lería-Gelabert M; Melogno-Klinkas M
    Curr Med Res Opin; 2020 Aug; 36(8):1383-1391. PubMed ID: 32453602
    [No Abstract]   [Full Text] [Related]  

  • 29. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
    Romualdi P; Candeletti S
    Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
    Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
    Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain.
    Darbà J; Kaskens L; Sánchez-de la Rosa R
    Clinicoecon Outcomes Res; 2013; 6():1-9. PubMed ID: 24368889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
    Überall MA
    MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
    Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
    J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fentanyl buccal tablets in the treatment of breakthrough cancer pain. German cohort of a pan-European multicentre study].
    Lux EA; Schwittay A; Kleeberg UR; Papke J
    MMW Fortschr Med; 2018 Jul; 160(Suppl 4):18-23. PubMed ID: 29974433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
    Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T
    Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.
    Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
    Drugs R D; 2019 Sep; 19(3):247-254. PubMed ID: 31177479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
    Pardo J; Mena A; Jiménez E; Aymar N; Ortiz I; Roncero R; Mestre F; Vidal M
    Clin Transl Oncol; 2019 Nov; 21(11):1568-1572. PubMed ID: 31093890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
    Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
    Jandhyala R; Fullarton JR; Bennett MI
    J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.